Even though most of the studies on PAPPA so far suggested its tumor-promoting role is largely IGF-1-dependent, anti-PAPPA therapy might provide therapeutic effects beyond the inhibition of the IGF-1/IGF-1R signaling axis. This evidence concerns the gene IGF1R and neoplasm.